AbbVie Says Canada's Drug Agency Recommends UBRELVY Be Reimbursed With Conditions By Public Drug Plans For Acute Treatment Of Migraine In Adults
UBRELVY® (ubrogepant) positive recommendation by Canada's Drug Agency (CDA-AMC) is supported by evidence from the pivotal Phase3 ACHIEVEI and ACHIEVEII studies.CDA-AMC recommendation recognizes the need for
Canada's government drug agency said it will help pay for AbbVie's migraine medicine UBRELVY, but with some rules attached. This is good news for the company because more people can afford to use their medicine.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.